Even As PBMs Face Reckoning, Formulary Exclusions Rise Again In 2023
• By Leslie Small
Congressional scrutiny aside, ‘the rebate model remains alive and well’ as the big three pharmacy benefit managers exclude around 600 drugs each from their formularies.
There's nothing strange in the neighborhood pharmacy about growing PBM exclusions. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images
With PBM execs slated to testify at a Senate hearing about drug costs on 10 May, scrutiny of pharmacy benefit managers seems be cemented as part of the drug pricing debate, thanks in large part to a successful campaign from their vendors/rivals, the pharmaceutical industry.
Final guidelines explaining how staff at Canada’s Patented Medicine Prices Review Board should go about identifying drugs that could be considered for an excessive price hearing will come into force soon.
The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.
The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.
The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.
The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.